nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—Actinic keratosis—Capecitabine—esophageal cancer	0.0253	0.0697	CcSEcCtD
Trametinib—Ocular toxicity—Cisplatin—esophageal cancer	0.0211	0.0582	CcSEcCtD
Trametinib—Seborrhoeic keratosis—Capecitabine—esophageal cancer	0.0201	0.0554	CcSEcCtD
Trametinib—MAP2K1—neck—esophageal cancer	0.0173	0.168	CbGeAlD
Trametinib—MAP2K1—epithelium—esophageal cancer	0.0118	0.114	CbGeAlD
Trametinib—MAP2K1—smooth muscle tissue—esophageal cancer	0.0113	0.11	CbGeAlD
Trametinib—MAP2K2—bronchus—esophageal cancer	0.0102	0.0991	CbGeAlD
Trametinib—MAP2K2—smooth muscle tissue—esophageal cancer	0.00999	0.097	CbGeAlD
Trametinib—Paronychia—Methotrexate—esophageal cancer	0.00904	0.0249	CcSEcCtD
Trametinib—MAP2K1—digestive system—esophageal cancer	0.00896	0.087	CbGeAlD
Trametinib—Lymphoedema—Capecitabine—esophageal cancer	0.00863	0.0238	CcSEcCtD
Trametinib—Blindness transient—Methotrexate—esophageal cancer	0.00859	0.0237	CcSEcCtD
Trametinib—MAP2K2—digestive system—esophageal cancer	0.00789	0.0766	CbGeAlD
Trametinib—MAP2K1—lung—esophageal cancer	0.00748	0.0726	CbGeAlD
Trametinib—Hyperkeratosis—Capecitabine—esophageal cancer	0.00737	0.0203	CcSEcCtD
Trametinib—Abdominal pain lower—Capecitabine—esophageal cancer	0.00663	0.0183	CcSEcCtD
Trametinib—MAP2K2—lung—esophageal cancer	0.00659	0.0639	CbGeAlD
Trametinib—Haematochezia—Capecitabine—esophageal cancer	0.00523	0.0144	CcSEcCtD
Trametinib—Rash macular—Capecitabine—esophageal cancer	0.00514	0.0142	CcSEcCtD
Trametinib—MAP2K1—lymph node—esophageal cancer	0.00512	0.0497	CbGeAlD
Trametinib—Hypophosphataemia—Cisplatin—esophageal cancer	0.00492	0.0136	CcSEcCtD
Trametinib—Prurigo—Capecitabine—esophageal cancer	0.00456	0.0126	CcSEcCtD
Trametinib—MAP2K2—lymph node—esophageal cancer	0.00451	0.0437	CbGeAlD
Trametinib—Cardiomyopathy—Capecitabine—esophageal cancer	0.00412	0.0114	CcSEcCtD
Trametinib—Lymphopenia—Capecitabine—esophageal cancer	0.00412	0.0114	CcSEcCtD
Trametinib—Night sweats—Capecitabine—esophageal cancer	0.0039	0.0108	CcSEcCtD
Trametinib—Mucosal inflammation—Capecitabine—esophageal cancer	0.00381	0.0105	CcSEcCtD
Trametinib—Infection—Carboplatin—esophageal cancer	0.00345	0.00952	CcSEcCtD
Trametinib—Hypomagnesaemia—Capecitabine—esophageal cancer	0.00332	0.00914	CcSEcCtD
Trametinib—Cellulitis—Cisplatin—esophageal cancer	0.00314	0.00866	CcSEcCtD
Trametinib—Hypercalcaemia—Capecitabine—esophageal cancer	0.00303	0.00836	CcSEcCtD
Trametinib—Vaginal haemorrhage—Capecitabine—esophageal cancer	0.00285	0.00785	CcSEcCtD
Trametinib—Mucosal inflammation—Methotrexate—esophageal cancer	0.00283	0.00781	CcSEcCtD
Trametinib—Hyperkalaemia—Cisplatin—esophageal cancer	0.00281	0.00774	CcSEcCtD
Trametinib—Rash erythematous—Capecitabine—esophageal cancer	0.00275	0.00758	CcSEcCtD
Trametinib—Body temperature increased—Carboplatin—esophageal cancer	0.00275	0.00758	CcSEcCtD
Trametinib—Polyp—Methotrexate—esophageal cancer	0.00258	0.00711	CcSEcCtD
Trametinib—Folliculitis—Methotrexate—esophageal cancer	0.0025	0.00688	CcSEcCtD
Trametinib—Cyst—Methotrexate—esophageal cancer	0.00235	0.00647	CcSEcCtD
Trametinib—Rectal haemorrhage—Capecitabine—esophageal cancer	0.00233	0.00643	CcSEcCtD
Trametinib—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00232	0.00639	CcSEcCtD
Trametinib—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.00232	0.00639	CcSEcCtD
Trametinib—Cellulitis—Capecitabine—esophageal cancer	0.00232	0.00639	CcSEcCtD
Trametinib—Hypocalcaemia—Capecitabine—esophageal cancer	0.0023	0.00634	CcSEcCtD
Trametinib—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00229	0.00631	CcSEcCtD
Trametinib—Renal failure acute—Cisplatin—esophageal cancer	0.00225	0.0062	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.00211	0.00581	CcSEcCtD
Trametinib—Hyponatraemia—Cisplatin—esophageal cancer	0.00208	0.00574	CcSEcCtD
Trametinib—Melaena—Capecitabine—esophageal cancer	0.00206	0.00567	CcSEcCtD
Trametinib—Dry eye—Capecitabine—esophageal cancer	0.00195	0.00536	CcSEcCtD
Trametinib—Blood creatinine increased—Cisplatin—esophageal cancer	0.00194	0.00536	CcSEcCtD
Trametinib—Dehydration—Cisplatin—esophageal cancer	0.00193	0.00532	CcSEcCtD
Trametinib—Neoplasm—Capecitabine—esophageal cancer	0.00191	0.00525	CcSEcCtD
Trametinib—Mouth ulceration—Capecitabine—esophageal cancer	0.00191	0.00525	CcSEcCtD
Trametinib—Hypokalaemia—Cisplatin—esophageal cancer	0.00189	0.00521	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00187	0.00515	CcSEcCtD
Trametinib—CYP3A4—digestive system—esophageal cancer	0.00185	0.018	CbGeAlD
Trametinib—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00176	0.00485	CcSEcCtD
Trametinib—Pancreatitis—Cisplatin—esophageal cancer	0.00176	0.00485	CcSEcCtD
Trametinib—Bone disorder—Methotrexate—esophageal cancer	0.00174	0.00479	CcSEcCtD
Trametinib—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.00172	0.00475	CcSEcCtD
Trametinib—Abdominal discomfort—Cisplatin—esophageal cancer	0.00172	0.00474	CcSEcCtD
Trametinib—Renal failure acute—Capecitabine—esophageal cancer	0.00166	0.00457	CcSEcCtD
Trametinib—Renal failure—Cisplatin—esophageal cancer	0.00157	0.00433	CcSEcCtD
Trametinib—Stomatitis—Cisplatin—esophageal cancer	0.00156	0.0043	CcSEcCtD
Trametinib—Hyponatraemia—Capecitabine—esophageal cancer	0.00154	0.00423	CcSEcCtD
Trametinib—Melaena—Methotrexate—esophageal cancer	0.00153	0.00422	CcSEcCtD
Trametinib—Pain in extremity—Capecitabine—esophageal cancer	0.00153	0.00422	CcSEcCtD
Trametinib—Bradycardia—Cisplatin—esophageal cancer	0.00146	0.00403	CcSEcCtD
Trametinib—Blood creatinine increased—Capecitabine—esophageal cancer	0.00143	0.00395	CcSEcCtD
Trametinib—Dehydration—Capecitabine—esophageal cancer	0.00142	0.00392	CcSEcCtD
Trametinib—Neoplasm—Methotrexate—esophageal cancer	0.00142	0.00391	CcSEcCtD
Trametinib—Mouth ulceration—Methotrexate—esophageal cancer	0.00142	0.00391	CcSEcCtD
Trametinib—Urinary tract disorder—Cisplatin—esophageal cancer	0.00142	0.00391	CcSEcCtD
Trametinib—Connective tissue disorder—Cisplatin—esophageal cancer	0.00141	0.00389	CcSEcCtD
Trametinib—Urethral disorder—Cisplatin—esophageal cancer	0.00141	0.00388	CcSEcCtD
Trametinib—Dry skin—Capecitabine—esophageal cancer	0.0014	0.00386	CcSEcCtD
Trametinib—Abdominal pain upper—Capecitabine—esophageal cancer	0.0014	0.00385	CcSEcCtD
Trametinib—Hypokalaemia—Capecitabine—esophageal cancer	0.00139	0.00384	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00138	0.0038	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00135	0.00372	CcSEcCtD
Trametinib—Eye disorder—Cisplatin—esophageal cancer	0.00134	0.0037	CcSEcCtD
Trametinib—Cardiac disorder—Cisplatin—esophageal cancer	0.00133	0.00367	CcSEcCtD
Trametinib—Mediastinal disorder—Cisplatin—esophageal cancer	0.00129	0.00357	CcSEcCtD
Trametinib—Arrhythmia—Cisplatin—esophageal cancer	0.00128	0.00353	CcSEcCtD
Trametinib—Abdominal discomfort—Capecitabine—esophageal cancer	0.00127	0.00349	CcSEcCtD
Trametinib—Erythema—Cisplatin—esophageal cancer	0.00125	0.00344	CcSEcCtD
Trametinib—Malnutrition—Cisplatin—esophageal cancer	0.00125	0.00344	CcSEcCtD
Trametinib—Neutropenia—Capecitabine—esophageal cancer	0.00124	0.00341	CcSEcCtD
Trametinib—Renal failure acute—Methotrexate—esophageal cancer	0.00123	0.0034	CcSEcCtD
Trametinib—Muscle spasms—Cisplatin—esophageal cancer	0.0012	0.00331	CcSEcCtD
Trametinib—Hyperglycaemia—Capecitabine—esophageal cancer	0.00119	0.00329	CcSEcCtD
Trametinib—Infestation NOS—Capecitabine—esophageal cancer	0.00118	0.00325	CcSEcCtD
Trametinib—Infestation—Capecitabine—esophageal cancer	0.00118	0.00325	CcSEcCtD
Trametinib—Vision blurred—Cisplatin—esophageal cancer	0.00118	0.00325	CcSEcCtD
Trametinib—Renal failure—Capecitabine—esophageal cancer	0.00116	0.00319	CcSEcCtD
Trametinib—Anaemia—Cisplatin—esophageal cancer	0.00115	0.00318	CcSEcCtD
Trametinib—Stomatitis—Capecitabine—esophageal cancer	0.00115	0.00317	CcSEcCtD
Trametinib—Urinary tract infection—Capecitabine—esophageal cancer	0.00115	0.00316	CcSEcCtD
Trametinib—Haematuria—Capecitabine—esophageal cancer	0.00112	0.0031	CcSEcCtD
Trametinib—Leukopenia—Cisplatin—esophageal cancer	0.00112	0.00308	CcSEcCtD
Trametinib—Epistaxis—Capecitabine—esophageal cancer	0.00111	0.00306	CcSEcCtD
Trametinib—Bradycardia—Capecitabine—esophageal cancer	0.00108	0.00297	CcSEcCtD
Trametinib—Myalgia—Cisplatin—esophageal cancer	0.00106	0.00293	CcSEcCtD
Trametinib—Haemoglobin—Capecitabine—esophageal cancer	0.00106	0.00293	CcSEcCtD
Trametinib—Haemorrhage—Capecitabine—esophageal cancer	0.00106	0.00292	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00106	0.00291	CcSEcCtD
Trametinib—Urinary tract disorder—Capecitabine—esophageal cancer	0.00105	0.00288	CcSEcCtD
Trametinib—Oedema peripheral—Capecitabine—esophageal cancer	0.00104	0.00287	CcSEcCtD
Trametinib—Connective tissue disorder—Capecitabine—esophageal cancer	0.00104	0.00287	CcSEcCtD
Trametinib—Urethral disorder—Capecitabine—esophageal cancer	0.00104	0.00286	CcSEcCtD
Trametinib—Oedema—Cisplatin—esophageal cancer	0.00102	0.00281	CcSEcCtD
Trametinib—Infection—Cisplatin—esophageal cancer	0.00101	0.00279	CcSEcCtD
Trametinib—Nervous system disorder—Cisplatin—esophageal cancer	0.001	0.00276	CcSEcCtD
Trametinib—Thrombocytopenia—Cisplatin—esophageal cancer	0.000999	0.00275	CcSEcCtD
Trametinib—Skin disorder—Cisplatin—esophageal cancer	0.000991	0.00273	CcSEcCtD
Trametinib—Eye disorder—Capecitabine—esophageal cancer	0.000989	0.00273	CcSEcCtD
Trametinib—Hyperhidrosis—Cisplatin—esophageal cancer	0.000986	0.00272	CcSEcCtD
Trametinib—Cardiac disorder—Capecitabine—esophageal cancer	0.000982	0.00271	CcSEcCtD
Trametinib—Pancreatitis—Methotrexate—esophageal cancer	0.000965	0.00266	CcSEcCtD
Trametinib—Angiopathy—Capecitabine—esophageal cancer	0.00096	0.00265	CcSEcCtD
Trametinib—Mediastinal disorder—Capecitabine—esophageal cancer	0.000954	0.00263	CcSEcCtD
Trametinib—Chills—Capecitabine—esophageal cancer	0.000949	0.00262	CcSEcCtD
Trametinib—Arrhythmia—Capecitabine—esophageal cancer	0.000945	0.00261	CcSEcCtD
Trametinib—Abdominal discomfort—Methotrexate—esophageal cancer	0.000943	0.0026	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000929	0.00256	CcSEcCtD
Trametinib—Mental disorder—Capecitabine—esophageal cancer	0.000927	0.00256	CcSEcCtD
Trametinib—Malnutrition—Capecitabine—esophageal cancer	0.000921	0.00254	CcSEcCtD
Trametinib—Erythema—Capecitabine—esophageal cancer	0.000921	0.00254	CcSEcCtD
Trametinib—Neutropenia—Methotrexate—esophageal cancer	0.00092	0.00254	CcSEcCtD
Trametinib—Dysgeusia—Capecitabine—esophageal cancer	0.000902	0.00249	CcSEcCtD
Trametinib—Back pain—Capecitabine—esophageal cancer	0.000891	0.00246	CcSEcCtD
Trametinib—Decreased appetite—Cisplatin—esophageal cancer	0.000887	0.00244	CcSEcCtD
Trametinib—Muscle spasms—Capecitabine—esophageal cancer	0.000886	0.00244	CcSEcCtD
Trametinib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00088	0.00243	CcSEcCtD
Trametinib—Infestation NOS—Methotrexate—esophageal cancer	0.000877	0.00242	CcSEcCtD
Trametinib—Infestation—Methotrexate—esophageal cancer	0.000877	0.00242	CcSEcCtD
Trametinib—Vision blurred—Capecitabine—esophageal cancer	0.000868	0.00239	CcSEcCtD
Trametinib—Renal failure—Methotrexate—esophageal cancer	0.000863	0.00238	CcSEcCtD
Trametinib—Stomatitis—Methotrexate—esophageal cancer	0.000855	0.00236	CcSEcCtD
Trametinib—Anaemia—Capecitabine—esophageal cancer	0.000851	0.00235	CcSEcCtD
Trametinib—Haematuria—Methotrexate—esophageal cancer	0.000837	0.00231	CcSEcCtD
Trametinib—Epistaxis—Methotrexate—esophageal cancer	0.000828	0.00228	CcSEcCtD
Trametinib—Leukopenia—Capecitabine—esophageal cancer	0.000825	0.00227	CcSEcCtD
Trametinib—Body temperature increased—Cisplatin—esophageal cancer	0.000806	0.00222	CcSEcCtD
Trametinib—Cough—Capecitabine—esophageal cancer	0.000804	0.00222	CcSEcCtD
Trametinib—Hypertension—Capecitabine—esophageal cancer	0.000795	0.00219	CcSEcCtD
Trametinib—Haemoglobin—Methotrexate—esophageal cancer	0.000792	0.00218	CcSEcCtD
Trametinib—Haemorrhage—Methotrexate—esophageal cancer	0.000788	0.00217	CcSEcCtD
Trametinib—Arthralgia—Capecitabine—esophageal cancer	0.000784	0.00216	CcSEcCtD
Trametinib—Myalgia—Capecitabine—esophageal cancer	0.000784	0.00216	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000779	0.00215	CcSEcCtD
Trametinib—Urinary tract disorder—Methotrexate—esophageal cancer	0.000778	0.00214	CcSEcCtD
Trametinib—Urethral disorder—Methotrexate—esophageal cancer	0.000772	0.00213	CcSEcCtD
Trametinib—Dry mouth—Capecitabine—esophageal cancer	0.000767	0.00211	CcSEcCtD
Trametinib—Oedema—Capecitabine—esophageal cancer	0.000752	0.00207	CcSEcCtD
Trametinib—Infection—Capecitabine—esophageal cancer	0.000747	0.00206	CcSEcCtD
Trametinib—Nervous system disorder—Capecitabine—esophageal cancer	0.000737	0.00203	CcSEcCtD
Trametinib—Eye disorder—Methotrexate—esophageal cancer	0.000736	0.00203	CcSEcCtD
Trametinib—Thrombocytopenia—Capecitabine—esophageal cancer	0.000736	0.00203	CcSEcCtD
Trametinib—Asthenia—Cisplatin—esophageal cancer	0.000732	0.00202	CcSEcCtD
Trametinib—Cardiac disorder—Methotrexate—esophageal cancer	0.000731	0.00202	CcSEcCtD
Trametinib—Skin disorder—Capecitabine—esophageal cancer	0.00073	0.00201	CcSEcCtD
Trametinib—Hyperhidrosis—Capecitabine—esophageal cancer	0.000727	0.002	CcSEcCtD
Trametinib—Angiopathy—Methotrexate—esophageal cancer	0.000715	0.00197	CcSEcCtD
Trametinib—Mediastinal disorder—Methotrexate—esophageal cancer	0.00071	0.00196	CcSEcCtD
Trametinib—Chills—Methotrexate—esophageal cancer	0.000707	0.00195	CcSEcCtD
Trametinib—Diarrhoea—Cisplatin—esophageal cancer	0.000698	0.00192	CcSEcCtD
Trametinib—Mental disorder—Methotrexate—esophageal cancer	0.00069	0.0019	CcSEcCtD
Trametinib—Erythema—Methotrexate—esophageal cancer	0.000686	0.00189	CcSEcCtD
Trametinib—Malnutrition—Methotrexate—esophageal cancer	0.000686	0.00189	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000685	0.00189	CcSEcCtD
Trametinib—Insomnia—Capecitabine—esophageal cancer	0.00068	0.00187	CcSEcCtD
Trametinib—Dysgeusia—Methotrexate—esophageal cancer	0.000672	0.00185	CcSEcCtD
Trametinib—Back pain—Methotrexate—esophageal cancer	0.000663	0.00183	CcSEcCtD
Trametinib—Decreased appetite—Capecitabine—esophageal cancer	0.000654	0.0018	CcSEcCtD
Trametinib—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000649	0.00179	CcSEcCtD
Trametinib—Vomiting—Cisplatin—esophageal cancer	0.000648	0.00179	CcSEcCtD
Trametinib—Fatigue—Capecitabine—esophageal cancer	0.000648	0.00179	CcSEcCtD
Trametinib—Vision blurred—Methotrexate—esophageal cancer	0.000646	0.00178	CcSEcCtD
Trametinib—Rash—Cisplatin—esophageal cancer	0.000643	0.00177	CcSEcCtD
Trametinib—Constipation—Capecitabine—esophageal cancer	0.000643	0.00177	CcSEcCtD
Trametinib—Dermatitis—Cisplatin—esophageal cancer	0.000642	0.00177	CcSEcCtD
Trametinib—Anaemia—Methotrexate—esophageal cancer	0.000634	0.00175	CcSEcCtD
Trametinib—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000615	0.00169	CcSEcCtD
Trametinib—Leukopenia—Methotrexate—esophageal cancer	0.000614	0.00169	CcSEcCtD
Trametinib—Nausea—Cisplatin—esophageal cancer	0.000606	0.00167	CcSEcCtD
Trametinib—Cough—Methotrexate—esophageal cancer	0.000598	0.00165	CcSEcCtD
Trametinib—Body temperature increased—Capecitabine—esophageal cancer	0.000594	0.00164	CcSEcCtD
Trametinib—Abdominal pain—Capecitabine—esophageal cancer	0.000594	0.00164	CcSEcCtD
Trametinib—Myalgia—Methotrexate—esophageal cancer	0.000584	0.00161	CcSEcCtD
Trametinib—Arthralgia—Methotrexate—esophageal cancer	0.000584	0.00161	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00058	0.0016	CcSEcCtD
Trametinib—Infection—Methotrexate—esophageal cancer	0.000556	0.00153	CcSEcCtD
Trametinib—Nervous system disorder—Methotrexate—esophageal cancer	0.000549	0.00151	CcSEcCtD
Trametinib—Thrombocytopenia—Methotrexate—esophageal cancer	0.000548	0.00151	CcSEcCtD
Trametinib—Skin disorder—Methotrexate—esophageal cancer	0.000544	0.0015	CcSEcCtD
Trametinib—Hyperhidrosis—Methotrexate—esophageal cancer	0.000541	0.00149	CcSEcCtD
Trametinib—Asthenia—Capecitabine—esophageal cancer	0.000539	0.00149	CcSEcCtD
Trametinib—Pruritus—Capecitabine—esophageal cancer	0.000532	0.00147	CcSEcCtD
Trametinib—Diarrhoea—Capecitabine—esophageal cancer	0.000514	0.00142	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00051	0.00141	CcSEcCtD
Trametinib—Insomnia—Methotrexate—esophageal cancer	0.000506	0.0014	CcSEcCtD
Trametinib—Dizziness—Capecitabine—esophageal cancer	0.000497	0.00137	CcSEcCtD
Trametinib—Decreased appetite—Methotrexate—esophageal cancer	0.000486	0.00134	CcSEcCtD
Trametinib—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000483	0.00133	CcSEcCtD
Trametinib—Fatigue—Methotrexate—esophageal cancer	0.000483	0.00133	CcSEcCtD
Trametinib—Vomiting—Capecitabine—esophageal cancer	0.000478	0.00132	CcSEcCtD
Trametinib—Rash—Capecitabine—esophageal cancer	0.000474	0.00131	CcSEcCtD
Trametinib—Dermatitis—Capecitabine—esophageal cancer	0.000474	0.00131	CcSEcCtD
Trametinib—Headache—Capecitabine—esophageal cancer	0.000471	0.0013	CcSEcCtD
Trametinib—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000458	0.00126	CcSEcCtD
Trametinib—Nausea—Capecitabine—esophageal cancer	0.000447	0.00123	CcSEcCtD
Trametinib—Abdominal pain—Methotrexate—esophageal cancer	0.000442	0.00122	CcSEcCtD
Trametinib—Body temperature increased—Methotrexate—esophageal cancer	0.000442	0.00122	CcSEcCtD
Trametinib—Asthenia—Methotrexate—esophageal cancer	0.000402	0.00111	CcSEcCtD
Trametinib—Pruritus—Methotrexate—esophageal cancer	0.000396	0.00109	CcSEcCtD
Trametinib—Diarrhoea—Methotrexate—esophageal cancer	0.000383	0.00106	CcSEcCtD
Trametinib—Dizziness—Methotrexate—esophageal cancer	0.00037	0.00102	CcSEcCtD
Trametinib—Vomiting—Methotrexate—esophageal cancer	0.000356	0.000981	CcSEcCtD
Trametinib—Rash—Methotrexate—esophageal cancer	0.000353	0.000973	CcSEcCtD
Trametinib—Dermatitis—Methotrexate—esophageal cancer	0.000353	0.000972	CcSEcCtD
Trametinib—Headache—Methotrexate—esophageal cancer	0.000351	0.000966	CcSEcCtD
Trametinib—Nausea—Methotrexate—esophageal cancer	0.000332	0.000916	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—TLR4—esophageal cancer	0.000143	0.000268	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—NOTCH1—esophageal cancer	0.000143	0.000267	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ENO1—esophageal cancer	0.00014	0.000263	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—PIK3CA—esophageal cancer	0.00014	0.000263	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PSME2—esophageal cancer	0.00014	0.000263	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PSME1—esophageal cancer	0.00014	0.000263	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—PIK3CA—esophageal cancer	0.00014	0.000262	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	0.00014	0.000261	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—FBXW7—esophageal cancer	0.000139	0.00026	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—BLVRB—esophageal cancer	0.000139	0.00026	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC52A3—esophageal cancer	0.000139	0.00026	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000139	0.00026	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HSPA5—esophageal cancer	0.000139	0.00026	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ELMO1—esophageal cancer	0.000138	0.000259	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PSME1—esophageal cancer	0.000138	0.000259	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PSME2—esophageal cancer	0.000138	0.000259	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—CREBBP—esophageal cancer	0.000138	0.000259	CbGpPWpGaD
Trametinib—MAP2K1—Disease—B2M—esophageal cancer	0.000137	0.000257	CbGpPWpGaD
Trametinib—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000137	0.000257	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000136	0.000254	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKAP13—esophageal cancer	0.000135	0.000253	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	0.000135	0.000253	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CALR—esophageal cancer	0.000135	0.000252	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—TLR4—esophageal cancer	0.000134	0.000251	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HMGB1—esophageal cancer	0.000133	0.000249	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CALR—esophageal cancer	0.000133	0.000249	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ENO1—esophageal cancer	0.000131	0.000246	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—PIK3CA—esophageal cancer	0.000131	0.000246	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—FBXW7—esophageal cancer	0.00013	0.000244	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ELMO1—esophageal cancer	0.00013	0.000243	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PSME1—esophageal cancer	0.000129	0.000242	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PSME2—esophageal cancer	0.000129	0.000242	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—CREBBP—esophageal cancer	0.000129	0.000242	CbGpPWpGaD
Trametinib—MAP2K2—Disease—FBXW7—esophageal cancer	0.000128	0.00024	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000127	0.000238	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKAP13—esophageal cancer	0.000127	0.000237	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000125	0.000234	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HMGB1—esophageal cancer	0.000124	0.000233	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—EGFR—esophageal cancer	0.000124	0.000233	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000124	0.000233	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CALR—esophageal cancer	0.000124	0.000233	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PDE4D—esophageal cancer	0.000124	0.000232	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CASP8—esophageal cancer	0.000123	0.00023	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CREBBP—esophageal cancer	0.000122	0.000229	CbGpPWpGaD
Trametinib—MAP2K1—Disease—FBXW7—esophageal cancer	0.00012	0.000225	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC10A2—esophageal cancer	0.000118	0.000221	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CA1—esophageal cancer	0.000118	0.000221	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GNG7—esophageal cancer	0.000118	0.00022	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000117	0.000219	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—EGFR—esophageal cancer	0.000116	0.000218	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—ERBB2—esophageal cancer	0.000116	0.000217	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PDE4D—esophageal cancer	0.000116	0.000217	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CASP8—esophageal cancer	0.000115	0.000215	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CREBBP—esophageal cancer	0.000114	0.000214	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—EGFR—esophageal cancer	0.000113	0.000211	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—XIAP—esophageal cancer	0.00011	0.000207	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GNG7—esophageal cancer	0.00011	0.000206	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ABL1—esophageal cancer	0.00011	0.000206	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—PIK3CA—esophageal cancer	0.00011	0.000206	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—ERBB2—esophageal cancer	0.000108	0.000203	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CA2—esophageal cancer	0.000108	0.000203	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—PIK3CA—esophageal cancer	0.000108	0.000202	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000106	0.000198	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—BCL2—esophageal cancer	0.000105	0.000197	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—EGFR—esophageal cancer	0.000105	0.000197	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CTNNA1—esophageal cancer	0.000104	0.000195	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFBR2—esophageal cancer	0.000104	0.000194	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL2—esophageal cancer	0.000104	0.000194	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—XIAP—esophageal cancer	0.000103	0.000193	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ABL1—esophageal cancer	0.000103	0.000193	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—PIK3CA—esophageal cancer	0.000103	0.000192	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—ERBB2—esophageal cancer	0.000102	0.000192	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—PIK3CA—esophageal cancer	0.000101	0.000189	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PLCE1—esophageal cancer	0.000101	0.000188	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ADH7—esophageal cancer	0.000101	0.000188	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	9.94e-05	0.000186	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—BCL2—esophageal cancer	9.86e-05	0.000185	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SMAD4—esophageal cancer	9.83e-05	0.000184	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CTNNA1—esophageal cancer	9.76e-05	0.000183	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFBR2—esophageal cancer	9.72e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL2—esophageal cancer	9.71e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PSME2—esophageal cancer	9.69e-05	0.000181	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PSME1—esophageal cancer	9.69e-05	0.000181	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ANXA1—esophageal cancer	9.65e-05	0.000181	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—ERBB2—esophageal cancer	9.58e-05	0.000179	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EP300—esophageal cancer	9.43e-05	0.000176	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SST—esophageal cancer	9.38e-05	0.000176	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SMAD4—esophageal cancer	9.2e-05	0.000172	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GHRL—esophageal cancer	9.14e-05	0.000171	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOTCH3—esophageal cancer	9.14e-05	0.000171	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PSME1—esophageal cancer	9.07e-05	0.00017	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PSME2—esophageal cancer	9.07e-05	0.00017	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ANXA1—esophageal cancer	9.02e-05	0.000169	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FBXW7—esophageal cancer	9e-05	0.000168	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ADH1B—esophageal cancer	8.82e-05	0.000165	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EP300—esophageal cancer	8.82e-05	0.000165	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SST—esophageal cancer	8.78e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CDKN1A—esophageal cancer	8.75e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GHRL—esophageal cancer	8.55e-05	0.00016	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOTCH3—esophageal cancer	8.55e-05	0.00016	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TYMP—esophageal cancer	8.43e-05	0.000158	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FBXW7—esophageal cancer	8.42e-05	0.000158	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—TLR4—esophageal cancer	8.34e-05	0.000156	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EP300—esophageal cancer	8.32e-05	0.000156	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOTCH2—esophageal cancer	8.2e-05	0.000154	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP26A1—esophageal cancer	8.2e-05	0.000153	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CDKN1A—esophageal cancer	8.19e-05	0.000153	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HIF1A—esophageal cancer	8.05e-05	0.000151	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EGFR—esophageal cancer	8.03e-05	0.00015	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALOX15—esophageal cancer	7.99e-05	0.00015	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—TLR4—esophageal cancer	7.8e-05	0.000146	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EP300—esophageal cancer	7.79e-05	0.000146	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOTCH2—esophageal cancer	7.67e-05	0.000144	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTO1—esophageal cancer	7.62e-05	0.000143	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TPI1—esophageal cancer	7.62e-05	0.000143	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HIF1A—esophageal cancer	7.53e-05	0.000141	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EGFR—esophageal cancer	7.52e-05	0.000141	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—BLVRB—esophageal cancer	7.47e-05	0.00014	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC52A3—esophageal cancer	7.47e-05	0.00014	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOS2—esophageal cancer	7.32e-05	0.000137	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALDOB—esophageal cancer	7.31e-05	0.000137	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFBR2—esophageal cancer	7.28e-05	0.000136	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOTCH1—esophageal cancer	7.25e-05	0.000136	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CASP8—esophageal cancer	7.15e-05	0.000134	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CREBBP—esophageal cancer	7.12e-05	0.000133	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EGFR—esophageal cancer	7.1e-05	0.000133	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GAPDH—esophageal cancer	7.03e-05	0.000132	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CRABP1—esophageal cancer	6.97e-05	0.00013	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SMAD4—esophageal cancer	6.89e-05	0.000129	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOS2—esophageal cancer	6.85e-05	0.000128	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFBR2—esophageal cancer	6.81e-05	0.000127	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOTCH1—esophageal cancer	6.78e-05	0.000127	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CASP8—esophageal cancer	6.69e-05	0.000125	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CREBBP—esophageal cancer	6.66e-05	0.000125	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EGFR—esophageal cancer	6.64e-05	0.000124	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GNG7—esophageal cancer	6.63e-05	0.000124	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CREBBP—esophageal cancer	6.57e-05	0.000123	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SMAD4—esophageal cancer	6.44e-05	0.000121	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC10A2—esophageal cancer	6.35e-05	0.000119	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CA1—esophageal cancer	6.35e-05	0.000119	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALDH2—esophageal cancer	6.21e-05	0.000116	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PIK3CA—esophageal cancer	6.16e-05	0.000115	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CREBBP—esophageal cancer	6.15e-05	0.000115	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—BCL2—esophageal cancer	6.14e-05	0.000115	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ERBB2—esophageal cancer	5.96e-05	0.000112	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTT1—esophageal cancer	5.91e-05	0.000111	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOS3—esophageal cancer	5.88e-05	0.00011	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP2A6—esophageal cancer	5.84e-05	0.000109	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	5.82e-05	0.000109	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CA2—esophageal cancer	5.81e-05	0.000109	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PIK3CA—esophageal cancer	5.76e-05	0.000108	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—BCL2—esophageal cancer	5.74e-05	0.000107	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HIF1A—esophageal cancer	5.63e-05	0.000105	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ERBB2—esophageal cancer	5.58e-05	0.000104	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS1—esophageal cancer	5.54e-05	0.000104	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ENO1—esophageal cancer	5.54e-05	0.000104	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOS3—esophageal cancer	5.51e-05	0.000103	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ERBB2—esophageal cancer	5.5e-05	0.000103	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PSME2—esophageal cancer	5.46e-05	0.000102	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PSME1—esophageal cancer	5.46e-05	0.000102	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PLCE1—esophageal cancer	5.4e-05	0.000101	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ADH7—esophageal cancer	5.4e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KDR—esophageal cancer	5.39e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTGS2—esophageal cancer	5.38e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HIF1A—esophageal cancer	5.27e-05	9.87e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ERBB2—esophageal cancer	5.15e-05	9.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDKN1A—esophageal cancer	5.1e-05	9.54e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOTCH1—esophageal cancer	5.08e-05	9.5e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KDR—esophageal cancer	5.04e-05	9.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—esophageal cancer	5.04e-05	9.43e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EP300—esophageal cancer	4.85e-05	9.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDKN1A—esophageal cancer	4.77e-05	8.92e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.77e-05	8.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOTCH1—esophageal cancer	4.75e-05	8.89e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ADH1B—esophageal cancer	4.73e-05	8.86e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP1B1—esophageal cancer	4.71e-05	8.81e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1A—esophageal cancer	4.7e-05	8.81e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CREBBP—esophageal cancer	4.6e-05	8.62e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EP300—esophageal cancer	4.54e-05	8.49e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TYMP—esophageal cancer	4.52e-05	8.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—esophageal cancer	4.52e-05	8.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EP300—esophageal cancer	4.48e-05	8.38e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP19A1—esophageal cancer	4.43e-05	8.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1A—esophageal cancer	4.4e-05	8.24e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	4.4e-05	8.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CREBBP—esophageal cancer	4.31e-05	8.06e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALOX15—esophageal cancer	4.29e-05	8.03e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—esophageal cancer	4.23e-05	7.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EP300—esophageal cancer	4.19e-05	7.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—esophageal cancer	4.13e-05	7.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOS3—esophageal cancer	4.12e-05	7.71e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TPI1—esophageal cancer	4.09e-05	7.66e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTO1—esophageal cancer	4.09e-05	7.66e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HMOX1—esophageal cancer	4.04e-05	7.56e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.96e-05	7.42e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CA—esophageal cancer	3.93e-05	7.35e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALDOB—esophageal cancer	3.92e-05	7.34e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—esophageal cancer	3.9e-05	7.3e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ABCB1—esophageal cancer	3.88e-05	7.26e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—esophageal cancer	3.87e-05	7.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOS3—esophageal cancer	3.86e-05	7.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ERBB2—esophageal cancer	3.85e-05	7.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—esophageal cancer	3.82e-05	7.14e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GAPDH—esophageal cancer	3.78e-05	7.07e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CRABP1—esophageal cancer	3.74e-05	7e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CA—esophageal cancer	3.67e-05	6.88e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—esophageal cancer	3.65e-05	6.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ERBB2—esophageal cancer	3.61e-05	6.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CA—esophageal cancer	3.59e-05	6.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—esophageal cancer	3.57e-05	6.68e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GNG7—esophageal cancer	3.56e-05	6.66e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—esophageal cancer	3.41e-05	6.38e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CA—esophageal cancer	3.36e-05	6.28e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALDH2—esophageal cancer	3.34e-05	6.24e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CA—esophageal cancer	3.31e-05	6.2e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1A—esophageal cancer	3.29e-05	6.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—esophageal cancer	3.19e-05	5.96e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTT1—esophageal cancer	3.17e-05	5.94e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	3.14e-05	5.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EP300—esophageal cancer	3.13e-05	5.87e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CA—esophageal cancer	3.1e-05	5.8e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1A—esophageal cancer	3.08e-05	5.77e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ENO1—esophageal cancer	2.97e-05	5.56e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.97e-05	5.56e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EP300—esophageal cancer	2.93e-05	5.49e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.93e-05	5.49e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PSME2—esophageal cancer	2.93e-05	5.48e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PSME1—esophageal cancer	2.93e-05	5.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—esophageal cancer	2.73e-05	5.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—esophageal cancer	2.67e-05	5e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CREBBP—esophageal cancer	2.59e-05	4.85e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—esophageal cancer	2.56e-05	4.78e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	2.53e-05	4.73e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—esophageal cancer	2.5e-05	4.68e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	2.38e-05	4.45e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NOS3—esophageal cancer	2.32e-05	4.34e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CA—esophageal cancer	2.32e-05	4.34e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—esophageal cancer	2.24e-05	4.2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CA—esophageal cancer	2.17e-05	4.06e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HMOX1—esophageal cancer	2.17e-05	4.06e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—esophageal cancer	2.12e-05	3.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—esophageal cancer	2.1e-05	3.93e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCB1—esophageal cancer	2.08e-05	3.9e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—EP300—esophageal cancer	1.77e-05	3.3e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.39e-05	2.6e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CA—esophageal cancer	1.31e-05	2.44e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NOS3—esophageal cancer	1.25e-05	2.33e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.14e-05	2.13e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—EP300—esophageal cancer	9.47e-06	1.77e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	7.01e-06	1.31e-05	CbGpPWpGaD
